H1O Stock Chart & Stats
€0.43
€0.00(0.00%)
At close: 4:00 PM EDT
€0.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.43 - €0.43
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.83M
Enterprise Value€8.48
Total Cash (Recent Filing)€7.89M
Total Debt (Recent Filing)€17.31K
Price to Earnings (P/E)―
Beta0.00
Next Earnings
Nov 24, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.90
Shares Outstanding7,018,528
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.04
Price to Sales (P/S)23.26
P/FCF Ratio-1.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.05Price Target Upside608.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.5
Revenue Forecast (FY)€129.09K
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage reduces near-term balance-sheet strain and preserves some financial flexibility while the company addresses operating challenges. Limited debt may also reduce interest burdens and give management more room to pursue restructuring or investment without immediate creditor pressure.
Positive Gross MarginA positive gross margin indicates the company retains some product-level economics after direct costs, providing a foundation for improvement if revenue can recover. This offers more potential operating leverage than a business that loses money before overhead and administration.
Experienced Consulting CFO AppointmentThe appointment adds experienced finance leadership at a time when reporting quality and capital discipline are important. The outsourced structure also preserves flexibility and controls fixed costs, potentially strengthening oversight without creating a large permanent expense commitment.
Bears Say
Severe Revenue ContractionA roughly 90% revenue decline signals a major deterioration in commercial scale and makes fixed operating costs harder to absorb. Unless sales stabilize and rebuild, the contraction can weaken market presence, reduce investment capacity, and prolong the company’s path toward sustainable profitability.
Persistent Deep LossesPersistent losses and an approximately negative 87% net margin show that the company has not yet established a sustainable earnings model. Continued operating deficits can consume resources, restrict strategic choices, and make future growth dependent on improved execution rather than proven profitability.
Ongoing Cash Burn And Funding RiskNegative operating and free cash flow across all provided periods means the business is not financing itself through operations. If current trends continue, external funding may be needed, increasing financing dependence and potentially creating dilution or other constraints on long-term shareholder value.
H1O FAQ
What was Vyome Holdings’s price range in the past 12 months?
Vyome Holdings lowest stock price was €0.43 and its highest was €0.43 in the past 12 months.
What is Vyome Holdings’s market cap?
Vyome Holdings’s market cap is €12.83M.
When is Vyome Holdings’s upcoming earnings report date?
Vyome Holdings’s upcoming earnings report date is Nov 24, 2026 which is in 65 days.
How were Vyome Holdings’s earnings last quarter?
Vyome Holdings released its earnings results on Aug 25, 2026. The company reported -€0.086 earnings per share for the quarter, beating the consensus estimate of -€0.164 by €0.078.
Is Vyome Holdings overvalued?
According to Wall Street analysts Vyome Holdings’s price is currently Undervalued.
Does Vyome Holdings pay dividends?
Vyome Holdings does not currently pay dividends.
What is Vyome Holdings’s EPS estimate?
Vyome Holdings’s EPS estimate is -0.14.
How many shares outstanding does Vyome Holdings have?
Vyome Holdings has 7,018,528 shares outstanding.
What happened to Vyome Holdings’s price movement after its last earnings report?
Vyome Holdings reported an EPS of -€0.086 in its last earnings report, beating expectations of -€0.164. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vyome Holdings?
Currently, no hedge funds are holding shares in DE:H1O
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vyome Holdings
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
H1O Stock 12 Month Forecast
Average Price Target
€3.05
▲(608.63% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
Collplant Holdings
―
Dermata Therapeutics
―
Azitra Inc
―
Polyrizon Ltd.
―










